Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
Kato K, Machida R, Ito Y, Daiko H, Ozawa S, Ogata T et al, on behalf of the JCOG1109 investigators.
Lancet 2024; 404: 55-66.
This three-arm trial included 601 patients, with median follow-up 50.7 months. Three-year overall survival was highest after triplet chemotherapy including docetaxel (72.1 per cent), compared to doublet chemotherapy (62.6 per cent) and additional radiotherapy (68.3 per cent).
Comment: Triplet chemotherapy could be the new standard of care, but patients need to be robust.
Published on: 3 November 2024
Article ID: BJS-2024-0132
Connect
